Akèy › Kansè pwostat › Texas › Dallas
Etid klinik pou Kansè pwostat nan Dallas, TX
36 etid pou Kansè pwostat ap chèche patisipan nan sit nan ak bò kote Dallas (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- UT Southwest Simmons Cancer Center, Dallas
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Ap rekriteFaz 3
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Ap rekriteFaz 2
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Ap rekriteFaz 2
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
DESTINY-PANTUMOUR04
Ap rekriteEtid obsèvasyon
- Research Site, Dallas
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Ap rekriteFaz 3
- Texas Oncology - DFW ( Site 8001), Dallas
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Ap rekriteFaz 3
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- University of Texas Southwestern Medical Center - William P. Clements, Jr., University Hospital, Dallas
- University of Texas Southwestern Simmons Cancer Center - Redbird, Dallas
- ak 2 plis
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Ap rekriteFaz 2/3
- Texas Oncology, Dallas
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
Ap rekriteFaz 1
- Mary Crowley Cancer Research, Dallas
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- Texas Oncology - DFW (Sammons CC), Dallas
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Ap rekriteFaz 3
- University of Texas Southwestern Medical Center, Dallas
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Ap rekriteFaz 3
- Parkland Health & Hospital System ( Site 0069), Dallas
- UT Southwestern Medical Center ( Site 0039), Dallas
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Ap rekriteFaz 3
- Urology Clinics of North Texas, Dallas
- University of Texas Southwestern Medical Center, Dallas
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
- SCRI at Mary Crowley, Dallas
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Ap rekriteFaz 3
- Urology Clinics Of North Texas, Dallas
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Ap rekriteFaz 2
- University of Texas Southwestern Medical Center, Dallas
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Ap rekriteFaz 1/2
- University of Texas Southwestern Medical Center, Dallas
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Ap rekriteFaz 3
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Ap rekriteFaz 2
- University of Texas Southwestern Medical Center, Dallas
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Ap rekriteFaz 1
- Mary Crowley Cancer Research, Dallas
- University of Texas Southwestern Medical Center, Dallas
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Ap rekriteFaz 3
- Dallas VA Medical Center, Dallas
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Ap rekriteFaz 1
- Urology Clinics of North Texas, Dallas
Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)
Ap rekriteFaz 2
- UT Southwestern Medical Center-Dallas, Dallas
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
Ap rekriteFaz 3
- UT Southwestern Medical Center, Dallas
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Ap rekriteFaz 4
- Univ of Texas Southwest Med Center, Dallas
Outcomes of Focal Ablation for Prostate Cancer
Ap rekriteEtid obsèvasyon
- UTSW, Dallas
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
Ap rekriteFaz 3
- UT Southwestern Medical Center, Dallas
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Ap rekriteFaz 1/2
- Research Site, Dallas
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- Mary Crowley Cancer Research, Dallas
- Baylor University Medical Center, Dallas
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Ap rekriteFaz 1
- Urology Clinics of North Texas, Dallas
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Ap rekriteFaz 4
- UT Southwestern Medical Center, Dallas
Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1
Ap rekriteEtid obsèvasyon
- Ut Southwestern Medical Center, Dallas
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site 120, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Dallas
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Ap rekriteFaz 3
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Customized TULSA-PRO Ablation Registry
Ap rekriteEtid obsèvasyon
- University of Texas Southwestern Medical Center, Dallas
Etid Kansè pwostat nan lòt vil
- New York City, NY103 etid
- Houston, TX76 etid
- Los Angeles, CA61 etid
- Boston, MA59 etid
- St. Louis, MO46 etid
- Chicago, IL45 etid
- San Francisco, CA45 etid
- Philadelphia, PA44 etid
- Baltimore, MD43 etid
- Nashville, TN42 etid
- Seattle, WA42 etid
- Washington, DC38 etid
Lòt etid nan Dallas
- Kansè nan tete55 etid
- Kansè Poumon ki pa ti selil52 etid
- Kansè Metastatik42 etid
- Ensifizyans kadyak42 etid
- Kansè (tout kalite)37 etid
- Kansè kolorektal33 etid
- Obèsite30 etid
- Kansè ovè28 etid
- Kansè vejik27 etid
- Kansè poumon27 etid
- Kansè Endomèt24 etid
- Maladi kadyovaskilè23 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.